Phreesia (PHR) Projected to Post Earnings on Wednesday

Phreesia (NYSE:PHR) is expected to be releasing its Q4 2026 results before the market opens on Wednesday, March 11th. Analysts expect Phreesia to post earnings of $0.10 per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Monday, March 30, 2026 at 5:00 PM ET.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. The firm’s revenue for the quarter was up 12.7% on a year-over-year basis. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Price Performance

Shares of NYSE PHR opened at $12.40 on Wednesday. The stock has a market cap of $747.60 million, a price-to-earnings ratio of -123.99 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia has a fifty-two week low of $11.31 and a fifty-two week high of $32.76. The firm’s 50-day simple moving average is $14.52 and its 200 day simple moving average is $20.07.

Analysts Set New Price Targets

Several research analysts recently issued reports on PHR shares. Royal Bank Of Canada started coverage on Phreesia in a research report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 target price on the stock. Mizuho set a $22.00 price objective on shares of Phreesia in a report on Wednesday, February 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a research note on Wednesday, January 28th. Zacks Research lowered shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Citigroup cut their price target on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Seventeen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Phreesia currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.12.

Insiders Place Their Bets

In related news, insider David Linetsky sold 6,038 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $98,781.68. Following the transaction, the insider owned 223,942 shares in the company, valued at approximately $3,663,691.12. This represents a 2.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Evan Roberts sold 6,268 shares of the stock in a transaction on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $102,544.48. Following the transaction, the insider directly owned 826,554 shares of the company’s stock, valued at approximately $13,522,423.44. This trade represents a 0.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 60,766 shares of company stock valued at $1,013,817. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

Hedge funds have recently made changes to their positions in the company. Van ECK Associates Corp grew its stake in shares of Phreesia by 78.7% during the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after acquiring an additional 1,102 shares during the period. State of Wyoming purchased a new stake in Phreesia during the fourth quarter valued at about $99,000. Tower Research Capital LLC TRC boosted its position in Phreesia by 332.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock worth $160,000 after purchasing an additional 4,313 shares during the period. State of Tennessee Department of Treasury purchased a new position in shares of Phreesia in the fourth quarter worth about $202,000. Finally, Creative Planning bought a new stake in shares of Phreesia in the third quarter valued at approximately $218,000. 92.10% of the stock is currently owned by institutional investors.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.